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Summary
Background In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ring vaccination 
with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first time that an Ebola vaccine 
has been used in an outbreak setting outside a clinical trial. Here we describe the safety of rVSV-ZEBOV candidate 
vaccine and operational feasibility of ring vaccination as a reactive strategy in a resource-limited rural setting.
Methods Approval for expanded access and compassionate use was rapidly sought and obtained from relevant 
authorities. Vaccination teams and frozen vaccine were flown to the outbreak settings. Rings of contacts and contacts 
of contacts were defined and eligible individuals, who had given informed consent, were vaccinated and followed up 
for 21 days under good clinical practice conditions.
Findings Between March 17 and April 21, 2016, 1510 individuals were vaccinated in four rings in Guinea, including 
303 individuals aged between 6 years and 17 years and 307 front-line workers. It took 10 days to vaccinate the first 
participant following the confirmation of the first case of Ebola virus disease. No secondary cases of Ebola virus 
disease occurred among the vaccinees. Adverse events following vaccination were reported in 47 (17%) 6–17 year olds 
(all mild) and 412 (36%) adults (individuals older than 18 years; 98% were mild). Children reported fewer arthralgia 
events than adults (one [<1%] of 303 children vs 81 [7%] of 1207 adults). No severe vaccine-related adverse events were 
reported.
Interpretation The results show that a ring vaccination strategy can be rapidly and safely implemented at scale in 
response to Ebola virus disease outbreaks in rural settings.
Funding WHO, Gavi, and the World Food Programme.
Copyright © The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY 4.0 license.
Introduction
Between 2013 and 2015, more than 28 000 cases of Ebola 
virus disease were reported across Guinea, Sierra Leone, 
and Liberia. In response to the epidemic, trials of several 
candidate vaccines were fast-tracked. In July, 2015, 
interim results from the Ebola ça Suffit ring vaccination 
phase 3 cluster-randomised trial1 of the rVSV-ZEBOV 
vaccine in Guinea were published. On the basis of 
interim analysis, the trial showed 100% (95% CI –74·7 to 
100%) vaccine efficacy, with 75·1% (95% CI –7·1 to 
94·2%) vaccine effectiveness at the cluster level, 
including herd immunity of unvaccinated members of 
clusters.1
Guinea was declared Ebola virus disease-free on 
Dec 29, 2015, and the trial ended on Jan 20, 2016, after the 
final participants completed the 84-day follow-up. 
Surveillance for Ebola virus continued, and on 
March 17, 2016, two new laboratory-confirmed cases of 
Ebola virus disease were identified in the Nzérékoré 
prefecture (Guinea) of the inland Guinée Forestière region.2
Here, we report on the implementation and impact of 
the ring vaccination strategy in Guinea during this 
flare-up. We also evaluate the vaccine safety in different 
populations and examine the dynamics of transmission 
at the level of the rings.
Method
Study design
Under compassionate use, ring vaccination used a 
simplified version of the ring Ebola virus vaccination trial 
protocol3: all rings were immediately vaccinated and 
follow-up of vaccinees was done 30 min after vaccination 
and on days 3, 14, and 21 (visits on days 42, 63, and 84 
were omitted).
We also used a similar operational approach to the one 
used for the Ebola ring vaccination trial3 and the activities 
were done in accordance with good clinical practice 
(GCP). Before the confirmation of the first case of Ebola 
virus disease in this outbreak, a GCP-trained team drawn 
from members of the Ebola ça Suffit trial was in Conakry 
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(Guinea) preparing for a cohort study on contacts of 
survivors of Ebola virus disease.
Immediately after the confirmation of the first case in 
March, 2016, and following a request by the national 
authorities, WHO prepared a protocol for submission 
to the national regulator (Direction Nationale de la 
Pharmacie et du Laboratoire) and Guinean Ethics 
Review Committee (Comité National d’Ethique pour la 
Recherche en Santé), and the WHO Ethics Review 
Committee. The request was for authorisation to 
provide the rVSV-ZEBOV vaccine to contacts of recently 
confirmed case of Ebola virus disease under expanded 
access and compassionate use. At the time of this 
outbreak, rVSV-ZEBOV was still an unlicensed product. 
Expanded access and compassionate use were 
unanimously authorised within 48 h.
In parallel, trial personnel were selected on the basis of 
their skills and role during the trial and flown to 
Nzérékoré, Guinée Forestière, with support from the 
World Food Programme. In total, 35 trial staff members 
were deployed to Guinée Forestière with the aim of being 
able to implement four rings in parallel.
Once the regulatory and ethical approvals were 
obtained, a team of social mobilisers engaged with the 
local authorities and communities to obtain local 
approval for the team to visit the area and enumerate 
the ring members. National authorities held meetings 
with local authorities and leaders to explain the 
objectives and the known information about the 
candidate vaccine. Community engagement was an 
important part of the activity, particularly because the 
region of Guinée Forestière had been Ebola virus-free 
for a year before this case and communities were 
understandably reluctant to accept that Ebola virus 
disease had returned.
Once community authorisation was obtained, an 
epidemiological team defined a ring by enumerating the 
contacts and contacts of contacts of the index case. Contacts 
were individuals who visited or were visited by the index 
case after the onset of symptoms; had lived in the same 
household; or were in close physical contact with the 
patient’s body, bodily fluids, clothes, or linen within the last 
21 days. Contacts of contacts were defined as neighbours, 
family, or extended family members who lived within the 
nearest geographical boundary of all contacts, and the 
household members of any high-risk contacts.3,4 High-risk 
contacts were defined as in the Ebola ça Suffit trial3 and 
included contacts who had either touched bodily fluids, bed 
linen, clothes, or dishes; had been in direct physical contact; 
or had slept or ate in the same household as the index case.
Another team assessed the enumerated contacts of 
contacts eligibility. All contacts of contacts were eligible 
to receive vaccination, except those individuals who were 
pregnant, breastfeeding, younger than 6 years of age, 
severely ill or immunocompromised, or had a history of 
anaphylaxis following vaccination. Because the vaccine 
was not yet licensed, written informed consent was 
obtained from contacts of contacts before vaccination, 
using thumbprint signatures if illiterate following 
oral explanation, and countersignature by a literate, 
independent witness.
Procedures
Vaccination was provided to eligible individuals who had 
given consent and who were screened for eligibility. 
A different team assessed any immediate reactions for 
30 min after vaccination. Another team visited 
participants at home on days 3, 14, and 21 following 
vaccination to document the potential occurrence of any 
serious adverse events. On days 3 and 14 after vaccination, 
Research in context
Evidence before this study
No licensed vaccines are available for the prevention of Ebola 
virus disease or other filovirus infections. The rVSV-ZEBOV 
candidate vaccine has been reported to be protective and well 
tolerated in adults in a phase 3 clinical trial. We searched 
MEDLINE and Embase without language restrictions for articles 
published from January, 1990, to July 20, 2017, to identify any 
published report of the use of an Ebola vaccine under expanded 
access, with the search terms “Ebola virus”, “vaccine”, “children”, 
“compassionate use”, and “expanded access”. To our knowledge, 
our manuscript is the first documentation on the use of an Ebola 
vaccine under expanded access during an outbreak, and is the 
first to report on the safety profile of vaccinated children at risk 
of Ebola virus transmission. Therefore, we could not do a 
detailed systematic review at this point.
Added value of this study
Our study illustrates how a ring vaccination strategy can be 
implemented in a rural setting and in combination with other 
public health interventions. Furthermore, our study comprises 
an unprecedented dataset of safety information in children 
older than 6 years following immunisation. Our results show 
that a ring vaccination strategy can be rapidly and effectively 
implemented at scale in response to Ebola virus disease 
outbreaks in rural settings and across borders.
Implications of all the available evidence
Our findings underscore the importance of the ring vaccination 
strategy to be considered for an Ebola virus disease outbreak 
response as a public health intervention. Additionally, our 
results suggest that the ring vaccination approach is compatible 
with the use of an experimental vaccine under expanded access, 
and that children older than 6 years should be included in the 
ring definition. Ring vaccination might have application in the 
delivery strategy of other vaccine candidates in epidemics of 
other viral haemorrhagic fevers or other emerging infectious 
diseases.
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we obtained information about any type of adverse event 
using a standardised questionnaire. We followed up all 
individuals with adverse events until recovery.
Current cold chain requirements need the vaccine to 
be kept at –80°C. The cold chain was organised from a 
logistical base in Conakry. Vaccine and cold chain 
Figure 1: Probable chain of transmission in Guinea, from February to April, 2016
(A) Chain of transmission. (B) Date of confirmed cases refers to date of an RT-PCR positive diagnosis. Reproduced from Diallo and colleagues,5 by permission of Oxford 
Journals. G=case in Guinea. L=case in Liberia. M=male case. F=female case. NA=not available. *Died. †Possible date of onset.
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materials were sent in several deployments by a dedicated 
helicopter with a trained logistician to supervise the 
transport. The passive vaccine storage device containing 
the vaccine (Arktek, Intellectual Ventures, Bellevue, WA, 
USA) was sent together with two additional Arktek 
devices without vaccine as back-up systems.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Following reports of the two confirmed cases of Ebola 
virus disease in Nzérékoré prefecture on March 17, 2016, 
the national Ebola virus surveillance system identified 
three additional probable cases of Ebola virus disease in 
the area with disease onset dates between Feb 15 and 
March 9, 2016 (figure 1). In total, seven confirmed cases 
of Ebola virus disease were reported during this flare-up 
in Guinea, with three suspected cases identified 
retrospectively (figure 1). Furthermore, three other cases 
were reported in the Montserrado district in Liberia 
(figure 1).
Subsequent epidemiological investigations suggested 
that the assumed primary case in the flare-up, a 
37-year-old woman (G2 in figure 1; disease onset was on 
Feb 15, 2016, and she died on Feb 27, 2016), might have 
been infected via sexual transmission from a male 
survivor of Ebola virus disease (G1) 14 months after 
being discharged from acute care.5
Of the two confirmed cases reported on March 17, 
2016 (G5 and G6), who were members of the same 
family, the case with the earliest disease onset date was 
specified as the index case (G5; a 9-year-old girl with 
disease onset on March 12, 2016, and who died on 
March 15, 2016), and ring vaccination commenced on 
March 23, 2016 (figure 1). Another member of the family 
(G8; a 60-year-old woman with unknown date of onset 
who died on March 27, 2016) had Ebola virus disease 
confirmed on March 26, 2016, but was not included in 
the ring because she was not identified by the 
investigators at the time of the ring definition (figure 1).
Three further confirmed cases were reported in 
Nzérékoré and three more rings were defined, including 
one with satellite sites in the neighbouring prefecture of 
Macenta (Guinea; figure 2). The reconstructed chain of 
transmission also suggests that G7’s infection led to one 
additional case in Mahakoïta, Macenta prefecture, and 
three cases in Montserrado district, Liberia.
Figure 2: Map of west Africa and location of Nzérékoré prefecture
The flight path indicates how the vaccination teams travelled from Conakry to Nzérékoré. The inset map indicates the location of the four rings defined by their index 
cases and their contacts and contacts of contacts, including those resident in satellite sites.
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Ring vaccination was readily accepted except in one 
area in Macenta (Mahakoïta). Here representatives had 
initially accepted the compassionate use of the vaccine. 
However, hesitancy spread from a neighbouring village 
towards the Ebola virus surveillance teams, which led 
this community to reject the offer of vaccination, and no 
C100 C101 C102 C103
Index cases used to define rings
Sex Female Male Female Female
Age (years) 9 40 10 23
Date of symptoms onset March 12, 2016 March 17, 2016 March 27, 2016 March 26, 2016
Time from onset (days)
To admission 5 NA 0 7
To confirmation 5 4 0 7
To inclusion 10 8 1 8
Status at inclusion Alive Dead Alive Dead
Localisation Rural Rural Rural Urban
Characteristics
Rings
Contacts of contacts 715 75 484 385
Sex
Male 436 (61%) 60 (80%) 251 (52%) 200 (52%)
Female 279 (39%) 15 (20%) 233/484 (48%) 185 (48%)
Age (years) 32 (19) 44 (22) 21 (18) 33 (13)
Age group
0–5 years 82 (11%) 4 (5%) 51 (11%) 0
6–17 years 112 (16%) 6 (8%) 170 (35%) 21 (5%)
≥18 years 521 (73%) 65 (87%) 263 (54%) 364 (95%)
Satellite sites 2 3 0 0
Household size 7 (4) 7 (4) 7 (4) 8 (6)
Adults per household 2 (1) 2 (1) 2 (1) 2 (1)
Vaccinees
Vaccinated 632/715 (88%) 68/75 (91%) 425/484 (88%) 385/385 (100%)
Children (6–17 years) 111/632 (18%) 5/68 (7%) 166/425 (39%) 21/385 (5%)
Front-line workers 91/632 (14%) 3/68 (4%) 52/425 (12%) 161/385 (42%)
Time from inclusion to vaccination (days) 5·0 (2·7) 0·5 (0·6) 3·0 (1·2) 1·4 (1·1)
Contact with index case
Contact of contact 462/632 (73%) 63/68 (93%) 407/425 (96%) 339/385 (88%)
Contact 170/632 (27%) 5/68 (7%) 18/425 (4%) 46/385 (12%)
High-risk contact 170/632 (27%) 5/68 (7%) 18/425 (4%) 44/385 (11%)
Compliance with follow-up visits for safety monitoring
Day 3 621/632 (98%) 67/68 (99%) 387/425 (91%) 382/385 (99%)
Day 14 602/631 (95%)* 63/68 (93%) 410/425 (96%) 381/383 (99%)†
Day 21 617/631 (98%)* 66/68 (97%) 423/425 (>99%) 381/383 (99%)†
Non-vaccinees
Individuals 83/715 (12%) 7/75 (9%) 59/484 (12%) 0/385 (0%)
Reason for not being vaccinated
Eligible not consenting 0 2/7 (29%) 3/59 (5%) 0
Eligible not present 0 1/7 (14%) 1/59 (2%) 0
Not eligible (pregnant, breastfeeding, or severely ill) 0 0 5/59 (8%) 0
Children <6 years old 82/83 (99%) 4/7 (57%) 50/59 (85%) 0
Not listed initially 1/83 (1%) 0 0 0
Data are n, n (%), n/N (%), or mean (SD), unless otherwise stated. NA=not available.*One serious adverse event (stroke) occurred between day 3 and day 14 after 
vaccination that led to hospital admission. †Two serious adverse events (both malaria) occurred between day 3 and day 14 after vaccination that led to hospital 
admission.
Table 1: Characteristics and individual demographics of the four vaccination rings during the Guinea outbreak response
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vaccination was implemented in this area. No further 
cases were detected in connection with the Mahakoïta 
case. Rings were not defined for G2, G3, G4, and G6 
because more than 60% of its contacts and contacts of 
contacts were included in previous rings.
In total, 1659 contacts of contacts in Guinée Forestière 
were enumerated in four rings (table 1). Among the 
listed contacts of contacts and after screening, 1510 (91%) 
were eligible for vaccination (table 1). All the eligible 
contacts of contacts gave consent to be vaccinated and 
were subsequently vaccinated. Vaccinees included 
303 individuals (20%) aged between 6 years and 17 years 
and 307 front-line workers (20%; table 1).
Although the delay from onset to confirmation of the 
index case was fairly consistent (between 4 days and 
7 days, except for index C102, who was diagnosed on the 
day of onset), the median delay from confirmation of 
index case to vaccination of individuals in the ring 
decreased from 10 days to 2 days as the outbreak 
progressed (figure 3). This reduction in time was mainly 
because of the time lead associated with the first ring, 
which included the time to obtain protocol approval by 
the national authorities, to organise the transport of the 
teams and material to the affected site, and for the 
teams to engage local authorities and community.
The average size of the four rings was 414 contacts of 
contacts, ranging from 75 to 715, about four times larger 
than the size of rings defined during the ring vaccination 
trial. The mean age varied between rings and ranged 
from 21 years to 44 years. One ring (C103) was recorded 
as having no children younger than 6 years. All rings had 
a similar median household size of around eight 
members, including two people older than 18 years 
(adults). Ring C100 had two satellites and ring C101 had 
three satellites (figure 2).
Among eligible contacts of contacts in rings, the 
percentage of eligible contacts of contacts vaccinated 
varied from 88% to 100%. The most common reason for 
not being vaccinated was ineligibility because of age, 
with 136 (91%) of 149 ineligible contacts of contacts not 
vaccinated because they were younger than 6 years 
(table 1). Most vaccinees were contacts of contacts 
(between 73% and 96%) rather than contacts (table 1). By 
contrast, almost all contacts were high-risk contacts of 
the index cases (table 1).
The timings of the follow-up visits on days 3, 14, and 
21 were also less variable in the later rings (figure 3). 
Overall, 47 6–17 year olds (17%) and 412 adults (36%) 
reported at least one adverse event following vaccination 
(table 2). Almost all adverse events occurred between 
31 min and 3 days (table 2). Adults most commonly 
reported headache (180 [15%]), muscle pain (157 [13%]), 
myalgia (149 [13%]), fatigue (119 [10%]), and arthralgia 
(81 [7%]), which is consistent with the frequency of 
Figure 3: Timeline of operations in the four rings in Guinea
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adverse events observed during the Ebola ça Suffit ring 
vaccination trial (table 2). Children aged 6–17 years most 
commonly reported headache (34 [12%]), muscle pain 
(ten [4%]), and myalgia (nine [3%]) in the overall analysis 
(table 2). Arthralgia symptoms were reported by one 
vaccinee (<1%) aged 6–17 years compared with 
81 vaccinees (7%) aged 18 years or older (table 2). Three 
serious adverse events were reported (one case of stroke, 
one malaria case, and one case diagnosed with both 
salmonellosis and malaria), which did not show any 
particular sign at the day 3 follow-up visit, and did not 
exhibit particular clinical manifestation associated with 
the rVSV-ZEBOV vaccine. We concluded that no severe 
adverse events were causally related to the vaccine 
(appendix).
After each ring completed vaccination, no cases were 
reported neither before nor 10 or more days after 
vaccination (figure 3). These findings are consistent with 
the final results of the ring vaccination trial,6 which 
showed no infection in vaccinees once 10 days had 
elapsed after vaccination. Moreover, none of the listed 
but ineligible contacts, including children under 6 years 
old, developed Ebola virus disease. All subsequent cases 
of Ebola virus disease were individuals who were either 
not enumerated in the rings as contacts of contacts, or 
were infected before the outbreak was identified.
Discussion
During March and April, 2016, more than 1500 
individuals in Guinea were vaccinated under 
compassionate use with the rVSV-ZEBOV vaccine in 
response to a flare-up of cases of Ebola virus disease. No 
cases of Ebola virus disease were observed among the 
vaccinees for 10 days or longer after vaccination, 
consistent with the interim analysis of the ring 
vaccination trial.1 Nor were further cases identified in 
unvaccinated ring members once vaccination was 
complete. The intervention also shows that the ring 
vaccination strategy can be implemented rapidly and at 
scale even in remote rural settings.
Three serious adverse events were reported in Guinea 
following vaccination but were not thought to be related to 
the vaccine administration. This outcome is consistent 
with the findings of the Ebola Ça Suffit! trial6 in the group 
0–30 min 31 min to 3 days 4–14 days Overall (0–14 days)
Response rate Frequency Response rate Frequency Response rate Frequency Response rate Frequency
Adults (≥18 years, n=1207)
Arthralgia 100% 0 97% 80 (7%) 96% 1 (<1%) 93% 81 (7%)
Diarrhoea 100% 0 97% 3 (<1%) 96% 0 93% 3 (<1%)
Fatigue 100% 1 (<1%) 97% 118 (10%) 96% 1 (<1%) 94% 119 (10%)
Fever 100% 0 97% 1 (<1%) 96% 0 93% 1 (<1%)
Headache 100% 0 97% 180 (15%) 96% 0 94% 180 (16%)
Induration 100% 0 97% 1 (<1%) 96% 0 93% 1 (<1%)
Injection pain 100% 1 (<1%) 97% 37 (3%) 96% 0 93% 38 (3%)
Muscle pain 100% 0 97% 157 (13%) 96% 0 94% 157 (14%)
Myalgia 100% 0 97% 149 (13%) 96% 0 94% 149 (13%)
Vomiting 100% 0 97% 2 (<1%) 96% 0 93% 2 (<1%)
Other adverse events 100% 2 (<1%) 97% 29 (2%) 96% 2 (<1%) 93% 33 (3%)
Any adverse events* 100% 3 (<1%) 97% 408 (35%) 96% 4 (<1%) 94% 412 (36%)
Children (6–17 years, n=303)
Arthralgia 100% 0 94% 1 (<1%) >99% 0 93% 1 (<1%)
Diarrhoea 100% 0 94% 2 (1%) >99% 0 93% 2 (1%)
Fatigue 100% 0 94% 3 (1%) >99% 1 (<1%) 93% 3 (1%)
Fever 100% 0 94% 0 >99% 0 93% 0
Headache 100% 0 94% 33 (12%) >99% 1 (<1%) 93% 34 (12%)
Induration 100% 0 94% 0 >99% 0 93% 0
Injection pain 100% 0 94% 0 >99% 0 93% 0
Muscle pain 100% 0 94% 10 (4%) >99% 0 94% 10 (4%)
Myalgia 100% 0 94% 9 (3%) >99% 0 94% 9 (3%)
Vomiting 100% 0 94% 0 >99% 0 93% 0
Other adverse events 100% 0 94% 3 (1%) >99% 1 (<1%) 93% 4 (1%)
Any adverse events* 100% 0 94% 47 (17%) >99% 2 (1%) 94% 47 (17%)
Data are % or n (%). Response rates were used to calculate the percentage of events for each line.*Response rate calculated as the proportion of individuals who answered all adverse event fields or reported at 
least one adverse events.
Table 2: Frequency of adverse events by time since vaccination
See Online for appendix
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of individuals aged older than 18 years, in which 80 serious 
adverse events were reported, but only one was related to 
vaccination. In previous safety studies,7 arthralgia has been 
noted as a side-effect; few cases were observed during 
compassionate use, and were primarily among adults. 
None were severe and all spontaneously resolved.
The interim results of the Guinea ring vaccination trial 
found no infection among vaccinees 10 days or longer 
after vaccination.1 During the 2016 Guinée Forestière 
compassionate use ring vaccination, no confirmed cases 
of Ebola virus disease were among vaccinees, nor were 
there further cases of Ebola virus disease reported within 
rings once vaccination was completed. Our data suggest 
that compassionate use ring vaccination together with 
the routine Ebola virus response strategies contributed to 
control this outbreak.
The operational efficiency of the ring vaccination teams 
improved over time. This improvement was in part 
facilitated by an effective partnership to ensure the 
transport of the cold chain and the teams. In the first 
ring, the median time from laboratory confirmation of 
the index case to vaccination of contacts and contacts of 
contacts was 10 days, and the follow-ups at days 3, 14, and 
21 overlapped; in the fourth ring, the median time to 
vaccination was 2 days. The follow-up visits for all rings 
occurred as planned and at consistent intervals.
Individuals who were pregnant, breastfeeding, severely 
ill, or younger than 6 years old were not eligible for 
vaccination and no safety data were collected from 
these populations. Because the rings are defined as 
socioepidemiological networks, eligible contacts of 
contacts outside the immediate geographical area were 
also traced for enrolment, in addition to households of 
any geographically distant high-risk contacts. Therefore, 
field operations required constant adjustments to ensure 
all eligible contacts of contacts were enumerated and 
vaccinated if they gave their consent.
Resistance to outbreak response was a common 
occurrence during the Ebola virus disease epidemic in 
Guinea and Liberia during 2014–15.8,9 The experience in 
Macenta reminds us that an adequate community 
engagement approach is crucial to ensure successful 
implementation of Ebola virus vaccination activities. The 
availability of the preliminary results on the efficacy 
of the rVSV-ZEBOV candidate vaccine—which was 
described in the information provided to eligible contacts 
of contacts—might have contributed to the high 
acceptance of vaccination, contact tracing, and other 
community Ebola virus control interventions, including 
among children.
In Liberia, a similar vaccination approach under 
expanded access was adopted following the first 
confirmed case of Ebola virus disease on April 1, 2016. 
The response involved the Centre for Disease Control 
and Prevention, UNICEF, WHO, the PREVAIL 
partnership, the Expanded Program on Immunization, 
and community mobilisation and health promotion 
teams. On the basis of the Ebola ça Suffit research 
protocol, modified for a public health response rather 
than a research protocol, geographical rings were defined 
around the three confirmed cases. In total, 234 individuals 
were vaccinated including 16 contacts, 213 contacts of 
contacts, and five health-care workers. No cases of Ebola 
virus disease were reported among those individuals 
vaccinated and no serious adverse events were identified 
through a passive follow-up.
This experience on the compassionate use of the 
rVSV-ZEBOV candidate vaccine under expanded access 
suggest that ring vaccination can be rapidly and 
effectively implemented as part of the Ebola virus 
response in case of future outbreaks. Potential 
operational barriers including requirements for GCP 
compliance, written documentation of informed consent, 
and a –80°C cold chain can be addressed to provide 
vaccination to remote, rural communities as part of 
Ebola virus outbreak response.
The rVSV-ZEBOV vaccine was granted access to the 
PRIority MEdicine (PRIME) scheme by the European 
Medicine Agency and Breakthrough Therapy designation 
by the US Food and Drug Administration. To date, the 
rVSV-ZEBOV vaccine is not licensed and has not been 
prequalified by WHO. Nevertheless, should an Ebola 
virus disease outbreak occur before the candidate vaccine 
is licensed, the WHO Strategic Advisory Group of Experts 
on Immunization recommended that the rVSV-ZEBOV 
vaccine be promptly deployed under the expanded access 
framework, with informed consent and in compliance 
with GCP. Ring vaccination is the recommended delivery 
strategy and should be adapted to the social and 
geographic conditions of the outbreak areas and include 
people at risk including but not limited to contacts and 
contacts of contacts; local and international health-care 
and front-line workers in the affected areas; and health-
care and front-line workers in areas at risk of expansion 
of the outbreak.
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